Monday, September 14, 2026

North Korea to Open Medical Tourism for Foreigners — Will It Work?

North Korea is revamping its tourism by promoting medical tourism, targeting foreign visitors to enhance healthcare and attract tourists.

Korean Pitcher Go Woo-suk Suspended for 10 Games: What Happened?

Minnesota Twins pitcher Go Woo-suk faces a 10-game suspension for using a foreign substance during a game, complicating his MLB prospects.

LS ELECTRIC wins tax incentive approval for Utah production base, accelerating expansion

LS ELECTRIC secures tax incentives for a $168M expansion in Utah, aiming to enhance its North American operations and production capacity.

Tag: Wegovy

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Unlocking the Future: How Genomic Testing Enhances GLP-1 Obesity Treatment for Asian Patients

NGeneBio is developing tests to identify which patients benefit from GLP-1 weight loss drugs like Wegovy and Mounjaro, assessing side effects.

Novo Nordisk vs Eli Lilly: Is Weight Loss Advertising Misleading?

Novo Nordisk sues Eli Lilly for misleading ads on obesity drugs, claiming false comparisons and seeking corrective action in court.

Wegovy Breaks Records: 3 Million Prescriptions in Just 5 Months – What You Need to Know

Wegovy surpasses 3 million prescriptions in 5 months, marking a significant milestone in the U.S. obesity treatment market.

Teen Prescriptions for GLP-1 Obesity Drugs Surge in Korea, Raising Misuse Concerns

Surge in GLP-1 obesity treatment prescriptions among teens raises concerns over misuse and potential health risks.

Why Are Weight-Loss Drugs So Much Pricier in South Korea?

South Korea faces high obesity treatment costs compared to China and Japan, with no insurance coverage, despite potential patent expirations.

Novo Nordisk’s Oral Wegovy Tops 3,000 Prescriptions in Its First Week—A Challenge to Injectable GLP-1s

Novo Nordisk's Wegovy oral treatment exceeds 3,000 prescriptions in its debut week, signaling a shift towards oral obesity medications.

Novo Nordisk’s Wegovy Pill Draws 3,000 Prescriptions in Its First Week—Is Oral GLP-1 Here to Stay?

Novo Nordisk's Wegovy oral obesity treatment saw over 3,000 prescriptions in its first week, indicating strong market demand.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.